CTOs on the Move

Talcomp

www.talcomp.com

 
Talcomp is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.talcomp.com
  • 2323 S Voss Rd Ste 640
    Houston, TX USA 77057
  • Phone: 713.781.0000

Executives

Name Title Contact Details

Similar Companies

Elkhart General Healthcare System

For 100 years, the highly skilled professionals of Elkhart General Hospital have been providing comprehensive medical care to Elkhart and surrounding communities.

Contemporary Life Saving Training

Contemporary Life Saving Training is a O Fallon, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmeriChoice of New York

AmeriChoice of New York is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sharn Inc

Sharn Inc is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.